3Misushima Y,Li H,Yoshida I,et al. Changes in clinical features of fungemia in a Japanese university hospital over a 12-year period [J]. Intern Med, 1996 ; 35(9) : 707-711.
4Yamakami Y, Tashiro Y, Tokimatus I, et al. Microbiological and clinical study of fungemia between 1981 and 1992 [J].Kansenshogaku Zasshi,1995; 69(8) :890-894.
6Boogaert M,Winston D J, Bow E J, et al. Intravenous and oral itraconazole versus itravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broadspectrum ntibacterial therapy [ J ]. Ann Intern Med,2001, 135(6) :412 -422.
7Meis JF, Verweij PE. Current management of fungal infections[J]. Drugs,2001,61 Suppl 1:13 -25.
8Braj T, Powederl YWG, Kobyashi GS, et al. Amphotericin B : Current understanding of mechanisms of action [J]. Antib Agents Chcm, 1990, 34:183 - 188.
9[5]Ebright JR,Rytel MW.Bacterial pneumonia in the elderly.J Am Geriatr Soc,1980,28:220.
10Ascioglu S, Rex JH, De Panw B, et al. Defining opportunistic invasive fungal infections in imm unocom prom ised patients with cancer and hematopoietic stem cell transplants:an international consensus. Clin Infect Dis,2002,34( 1 ) :7 - 14.
